BridgeBio Pharma, Inc.
BBIO
$76.08
$1.321.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 10.89% | -8.02% | -35.31% | -81.63% | -71.08% |
| Total Depreciation and Amortization | -7.88% | -7.41% | -10.55% | -14.73% | -13.89% |
| Total Amortization of Deferred Charges | -7.68% | 1.50% | 20.89% | 78.48% | -- |
| Total Other Non-Cash Items | 73.77% | 2,676.70% | 1,133.32% | 544.48% | 1,689.94% |
| Change in Net Operating Assets | -2.81% | -142.27% | -259.37% | -313.58% | -293.00% |
| Cash from Operations | 33.77% | 11.28% | 14.37% | -29.90% | -58.07% |
| Capital Expenditure | -30.46% | -389.92% | -17.58% | 15.90% | 51.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 100.00% | 57.14% |
| Other Investing Activities | -258.99% | -275.11% | -137.81% | -118.74% | -67.43% |
| Cash from Investing | -270.36% | -280.13% | -140.29% | -120.91% | -67.84% |
| Total Debt Issued | -54.00% | -13.26% | -7.89% | 205.56% | 205.56% |
| Total Debt Repaid | 92.82% | 99.56% | 2.62% | 2.62% | 2.62% |
| Issuance of Common Stock | 204.27% | 424.79% | -89.43% | -92.58% | -97.16% |
| Repurchase of Common Stock | -316.80% | -80.38% | -703.37% | -532.36% | -443.61% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 32.32% | 8.36% | 39.43% | -150.99% | -87.40% |
| Cash from Financing | -52.44% | 60.39% | -52.00% | 209.41% | 45.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -135.25% | 420.00% | -138.51% | 304.04% | -10.35% |